Nav: Home

New outcomes study reports TYSABRI patients show overall improvement in cognition and quality of life, with lower levels of fatigue

April 29, 2009

Seattle, Wash. - April 29, 2009 - Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced results from an ongoing, one-year longitudinal health outcomes study (n=1275) in which patients who received three infusions of TYSABRI® (natalizumab) reported reduced fatigue, as well significant improvements in general and disease-specific measurements of quality of life (QoL) and cognitive function. Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with TYSABRI in usual-care settings. The results from this study are being presented today in two separate posters at the 61st Annual Meeting of the American Academy of Neurology.

"MS is a debilitating disease that significantly reduces the quality of patients' lives. In this study, a majority of patients said they were less tired, thought more clearly, and had a better overall quality of life," said Dr. William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "Data from the pivotal trial has shown that TYSABRI not only results in a significant reduction in relapses, but also showed an improvement in quality of life. These new patient-reported outcomes expand our understanding of the real-world impact of TYSABRI on different aspects of the lives of MS patients."

The ongoing one-year follow-up study will assess health outcomes from patients' perspectives before starting TYSABRI and after the third, sixth, and 12th infusions of TYSABRI, respectively. A majority of the patients in the study are female (78.4%) with mean age of 45.3 years and mean disease duration of 10 years.

Quality of Life Study Results

As early as after the third infusion of TYSABRI, patients reported statistically significant improvement in:
  • general health-related QoL, as measured by the 12-item Short Form Scale (SF-12), with higher scores indicating better QoL
  • MS-specific QoL, as measured by the 29-item Multiple Sclerosis Impact Scale (MSIS-29), with lower scores indicating better QoL
Both scales report the physical and psychological aspects of QoL in two summary scores. SF-12 physical component summary (baseline 34.03 vs. 36.02 at the 3rd infusion; p<0.001) and the SF-12 mental component summary score (baseline 43.17 vs. 47.22 at the 3rd infusion; p<0.001) showed statistically significant improvements from baseline.

For the MSIS-29 subscales, there were statistically significant improvements from baseline for both the physical (baseline 48.25 vs. 40.19; p<0.001) and psychological (baseline 43.70 vs. 34.80; p<0.001) impact scores.

The results of the current study are consistent with those reported in clinical trials and an earlier cross-sectional study in which patients reported significant improvements in functional status, disability and overall QoL after three TYSABRI infusions. The cross-sectional study also found that TYSABRI patients who had the disease for less than five years had higher magnitudes of improvement in functional status and overall QoL as compared to patients who had the disease for more than five years. Findings from this study will also be reported in the peer-reviewed journal The Patient: Patient-Centered Outcomes Research later this quarter.

The poster Change in Health-Related Quality of Life in Multiple Sclerosis Patients Receiving Natalizumab (P05.144) will be available for viewing on Wednesday, April 29, 2009, 11:30 a.m. PDT.

Cognition and Fatigue Study Results

After three infusions of TYSABRI, patients reported both:
  • improvements in cognitive functioning
  • lower impact of fatigue on daily functioning
Cognitive functioning was assessed by Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale) with higher scores indicating improved cognition. Impact of fatigue on daily functioning was assessed by short version of Modified Fatigue Impact Scale (MFIS-5) with lower scores indicating lower fatigue.

On average, MOS-Cog scores increased by statistical significance from baseline (baseline score 24.48; 3rd infusion score 26.29, p<0.001) and MFIS scores decreased by statistical significance from baseline (baseline score 12.46; 3 rd infusion score 10.29, p<0.001).

The poster Early Effects of Natalizumab on Patient Reported Fatigue and Cognitive Function (P02.142) will be available for viewing on Wednesday, April 29, 2009, 11:30 a.m. PDT.
-end-
About TYSABRI

TYSABRI is a treatment approved for relapsing forms of MS in the U.S. and relapsing-remitting MS in the European Union. According to data that have been published in the New England Journal of Medicine, after two years, TYSABRI treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001).

In early 2008, TYSABRI was approved in the U.S. to induce and maintain clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha. According to the US full prescribing information, among patients who responded to TYSABRI, 54% sustain their response through every visit for one year compared to 20% of patients receiving placebo (p<0.001), for a treatment difference of 34%.

TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI as monotherapy. Other serious adverse events that have occurred in TYSABRI-treated patients included hypersensitivity reactions (e.g., anaphylaxis) and infections. Serious opportunistic and other atypical infections have been observed in TYSABRI-treated patients, some of whom were receiving concurrent immunosuppressants. Herpes infections were slightly more common in patients treated with TYSABRI. In MS and CD clinical trials, the incidence and rate of other serious adverse events, including serious infections, were similar in patients receiving TYSABRI and those receiving placebo. Common adverse events reported in TYSABRI-treated MS patients include headache, fatigue, infusion reactions, urinary tract infections, joint and limb pain and rash. Other common adverse events reported in TYSABRI-treated CD patients include respiratory tract infections and nausea. Clinically significant liver injury has been reported in patients treated with TYSABRI in the post-marketing setting.

TYSABRI is approved in more than 40 countries.

For more information about TYSABRI please visit www.tysabri.com, www.biogenidec.com or www.elan.com or call 1-800-456-2255.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

INVESTOR CONTACTS:
Biogen Idec
Eric Hoffman
Ph: 617 679 2812

Elan
Chris Burns
Ph: + 353 1 709 4444
or
800 252 3526

David Marshall
Ph: +353 1 709 4444

GCI Health

Related Cognitive Function Articles:

Poverty may be more critical to cognitive function than trauma in adolescent refugees
For approximately a decade, research has examined whether trauma or poverty is the most powerful influence on children's cognitive abilities.
Insulin nasal spray may boost cognitive function in obese adolescents by improving connectivity
Researchers at the Modern Diet and Physiology Research Center and Department of Pediatrics at Yale School of Medicine are investigating whether insulin delivered directly to the brain by nasal inhalation can enhance communication between brain regions and improve cognition in adolescents with obesity and prediabetes.
Dietary supplement boosts cognitive function in vegetarians
Vegetarians who take the dietary supplement creatine may enjoy improved brain function, according to a new study.
Debt relief improves psychological and cognitive function, enabling better decision-making
A new study by the Social Service Research Centre at the National University of Singapore demonstrates that reducing the number of debt accounts lowers the mental burden of the poor, thereby improving psychological and cognitive performance.
Does pregnancy history affect cognitive function?
Healthy cognitive aging is a public health priority, especially as the US population grows older.
Does cognitive function affect oral health during aging?
In a Community Dentistry & Oral Epidemiology study, poor cognitive function in older adults was associated with poorer oral health and higher risk of tooth loss in later life.
Stem cell-derived neurons stop seizures and improve cognitive function
About 3.4 million Americans, or 1.2 percent of the population, have active epilepsy.
Mind-body exercises may improve cognitive function as adults age
Mind-body exercises -- especially tai chi and dance mind-body exercise -- are beneficial for improving global cognition, cognitive flexibility, working memory, verbal fluency, and learning in older adults.
Cancer treatments may affect cognitive function by accelerating biological aging
Cancer treatments are suspected to accelerate certain aging processes in the body.
New radiation treatment for brain cancer offers better preservation of cognitive function
When it comes to radiation therapy to treat brain cancer, hippocampal-avoidance whole-brain radiotherapy in conjunction with the drug memantine better preserved patients' cognitive function and demonstrated similar cancer control outcomes, compared to traditional whole-brain radiotherapy with memantine.
More Cognitive Function News and Cognitive Function Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab